Page last updated: 2024-10-26

doxylamine and Emesis

doxylamine has been researched along with Emesis in 39 studies

Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.

Research Excerpts

ExcerptRelevanceReference
"We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy."9.248-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017)
"Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy."9.20Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015)
"Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy."9.19Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014)
" The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)."9.16Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012)
"To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy."9.14Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010)
"Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries."7.79Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013)
"A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada."7.71The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001)
"An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking."7.30Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2  ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023)
"We report information about an unpublished 1970s study ("8-way" Bendectin Study) that aimed to evaluate the relative therapeutic efficacy of doxylamine, pyridoxine, and dicyclomine in the management of nausea and vomiting during pregnancy."5.248-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information. ( Persaud, N; Zhang, R, 2017)
"Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy."5.20Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015)
"Our investigation showed ondansetron to be superior to the combination of pyridoxine and doxylamine in the treatment of nausea and emesis in pregnancy."5.19Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial. ( Capp, SM; Carstairs, SD; Oliveira, LG; Riffenburgh, RH; You, WB, 2014)
" The authors' objective is to identify the determinants of adherence to delayed-release doxylamine-pyridoxine (Diclectin) in patients with nausea and vomiting of pregnancy (NVP)."5.16Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy. ( Caritis, S; Chiossi, G; Clark, S; Costantine, MM; Hankins, GD; Koren, G; Matok, I; Miodovnik, M; Umans, JG, 2012)
"To evaluate the effectiveness of Diclectin (doxylamine succinate 10 mg-pyridoxine hydrochloride 10 mg, delayed-release preparation) as compared with placebo for nausea and vomiting of pregnancy."5.14Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. ( Caritis, SN; Clark, S; Hankins, GD; Koren, G; Mattison, DR; Miodovnik, M; Umans, JG, 2010)
" We used as a motivating example the possible teratogenic risks of antiemetic agents in pregnancy since a large observational study recently showed that first-trimester exposure to doxylamine-pyridoxine was associated with significantly increased risk of congenital malformations as a whole, as well as central nervous system defects, and previous observational studies did not show such associations."5.12Misleading meta-analyses of observational studies may generate unjustified alarms: The case of medications for nausea and vomiting in pregnancy. ( Biffi, A; Cetin, I; Corrao, G; Filippelli, A; Locatelli, A; Rea, F, 2021)
"A double-blind comparison was undertaken between Debendox with 10mg of extra pyridoxine and placebo with 10mg of pyridoxine, in 56 women suffering from nausea and/or vomiting during the first 10 weeks of pregnancy."5.04Treatment of pregnancy sickness. ( Wheatley, D, 1977)
"For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo."4.93Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. ( Beyer, F; Bradley, J; Bryant, A; McParlin, C; Moloney, E; Muirhead, CR; Nelson-Piercy, C; Newbury-Birch, D; Norman, J; O'Donnell, A; Robson, SC; Shaw, C; Simpson, E; Swallow, B; Vale, L; Yates, L, 2016)
"Using the Quebec Pregnancy Cohort (1998-2015), first-trimester doxylamine-pyridoxine, metoclopramide, and ondansetron exposures were assessed for their association with MCM."3.91New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy. ( Bérard, A; Bernatsky, S; Gorgui, J; Sheehy, O; Soares de Moura, C; Zhao, JP, 2019)
"Diclectin (pyridoxine 10 mg and doxylamine 10 mg) has traditionally been used to treat nausea and vomiting of pregnancy (NVP); however, this drug is unavailable in many countries."3.79Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. ( Ashkenazi-Hoffnung, L; Klinger, G; Merlob, P; Stahl, B, 2013)
"Diclectin, composed of 10 mg doxylamine succinate (DOX) and 10 mg pyridoxine hydrochloride, is the drug combination of choice for the management of nausea and vomiting during pregnancy in Canada."3.77Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). ( Garcia-Bournissen, F; Gill, SK; Koren, G, 2011)
"Women who called the Motherisk NVP helpline, and were taking only Diclectin (vitamin B6 10 mg and doxylamine 10 mg), were enrolled in the study and assessed for the severity of nausea and vomiting of pregnancy (NVP) with the Motherisk-PUQE (pregnancy-unique quantification of emesis and nausea) scoring system."3.72Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. ( Boskovic, R; Einarson, A; Koren, G; Maltepe, C; Wolpin, J, 2003)
"A delayed-release combination of doxylamine-pyridoxine (D-P) (Diclectin) is the only approved antiemetic medication for use in pregnancy in Canada."3.71The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. ( Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001)
"I have a 30-year-old pregnant patient who is asthmatic and is taking prednisone."3.70Managing women with nausea and vomiting of pregnancy. Canadian consensus. ( , 2000)
"An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking."3.30Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2  ( An, CM; Cao, YJ; Chen, XY; Cong, J; Cui, YM; Feng, YH; Gao, JS; Hu, YH; Li, J; Li, L; Liu, JP; Liu, L; Liu, YX; Liu, ZL; Liu, ZS; Lu, ZL; Ma, HL; Mol, BWJ; Ng, EHY; Painter, RC; Qi, X; Qin, HC; Wang, CC; Wang, Y; Wang, YX; Wu, Q; Wu, XK; Yan, Y; Yang, XM; Yu, L; Zhang, B; Zhou, LL, 2023)
"Nausea and vomiting are common in early pregnancy."2.50The pharmacologic management of nausea and vomiting of pregnancy. ( Briggs, GG; Niebyl, JR, 2014)
"Phenothiazines should be reserved for treating persistent vomiting that threatens the maternal nutritional status."2.37Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy. ( Leathem, AM, 1986)

Research

Studies (39)

TimeframeStudies, this research(%)All Research%
pre-199012 (30.77)18.7374
1990's0 (0.00)18.2507
2000's11 (28.21)29.6817
2010's13 (33.33)24.3611
2020's3 (7.69)2.80

Authors

AuthorsStudies
Saz-Leal, P1
Zamorano-Domínguez, L1
Frías, J1
Guerra, P1
Saura-Valls, M1
Roca-Juanes, R1
Nebot-Troyano, J1
García-Aguilar, E1
Vilchez, T1
Urso, K1
Wu, XK1
Gao, JS1
Ma, HL1
Wang, Y1
Zhang, B1
Liu, ZL1
Li, J1
Cong, J1
Qin, HC1
Yang, XM1
Wu, Q1
Chen, XY1
Lu, ZL1
Feng, YH1
Qi, X1
Wang, YX1
Yu, L1
Cui, YM1
An, CM1
Zhou, LL1
Hu, YH1
Li, L1
Cao, YJ1
Yan, Y1
Liu, L1
Liu, YX1
Liu, ZS1
Painter, RC1
Ng, EHY1
Liu, JP1
Mol, BWJ1
Wang, CC1
Biffi, A1
Rea, F1
Locatelli, A1
Cetin, I1
Filippelli, A1
Corrao, G1
Bérard, A1
Sheehy, O1
Gorgui, J1
Zhao, JP1
Soares de Moura, C1
Bernatsky, S1
Ashkenazi-Hoffnung, L1
Merlob, P1
Stahl, B1
Klinger, G1
Niebyl, JR1
Briggs, GG1
Madjunkova, S1
Maltepe, C3
Koren, G10
Oliveira, LG1
Capp, SM1
You, WB1
Riffenburgh, RH1
Carstairs, SD1
Clark, S3
Hankins, GD3
Caritis, SN2
Umans, JG3
Miodovnik, M3
Mattison, DR2
Matok, I2
McParlin, C1
O'Donnell, A1
Robson, SC1
Beyer, F1
Moloney, E1
Bryant, A1
Bradley, J1
Muirhead, CR1
Nelson-Piercy, C1
Newbury-Birch, D1
Norman, J1
Shaw, C1
Simpson, E1
Swallow, B1
Yates, L1
Vale, L1
Zhang, R1
Persaud, N1
Nulman, I1
Rovet, J1
Barrera, M1
Knittel-Keren, D1
Feldman, BM1
Gill, SK1
Garcia-Bournissen, F2
Costantine, MM1
Chiossi, G1
Caritis, S1
Brent, R2
Kutcher, JS1
Engle, A1
Firth, J1
Lamm, SH1
Quinla, JD1
Hill, DA1
TOWNE, JE1
GEIGER, CJ1
FAHRENBACH, DM1
HEALEY, FJ1
Boskovic, R1
Einarson, A1
Wolpin, J1
Staroselsky, A1
Huff, PS1
David, TJ1
Mitchell, AA1
Rosenberg, L1
Shapiro, S1
Slone, D1
Harron, DW1
Griffiths, K1
Shanks, RG1
Mazzotta, P1
Navioz, Y2
Magee, LA1
Atanackovic, G1
Moretti, ME1
Strong, TH1
Wheatley, D1
Check, WA1
Shiono, PH1
Klebanoff, MA1
Leathem, AM1
Walters, WA1
Elbourne, D1
Mutch, L1
Dauncey, M1
Campbell, H1
Samphier, M1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022[NCT06055192]200 participants (Anticipated)Observational2023-09-30Not yet recruiting
Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy[NCT01668069]36 participants (Actual)Interventional2012-10-31Completed
A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy[NCT00614445]Phase 3280 participants (Actual)Interventional2008-01-31Completed
Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?[NCT02960113]Phase 4240 participants (Actual)Interventional2016-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).

The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe). (NCT00614445)
Timeframe: Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)

InterventionPUQE Score (Mean)
Diclectin®-4.8
Placebo-3.9

Level of Nausea After Eversion of the Uterus

Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after eversion of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After eversion of the uterus until replacement of the uterus

Interventionunits on a scale (Mean)
Scopolamine Patch1.28
Acupressure Point P61.09
Scopolamine Patch + Acupressure Point P61.40

Level of Nausea After Replacement of the Uterus

Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after replacement of the uterus. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: After replacement of the uterus and to the next 15 minutes

Interventionunits on a scale (Mean)
Scopolamine Patch2.19
Acupressure Point P62.19
Scopolamine Patch + Acupressure Point P62.51

Level of Nausea After the Administration of the Regional Anesthesia Medications

Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) after the administration of the regional anesthesia medications. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: From administration of anaesthesia until eversion of uterus

Interventionunits on a scale (Mean)
Scopolamine Patch2.71
Acupressure Point P62.57
Scopolamine Patch + Acupressure Point P62.84

Level of Nausea Upon Arrival to the Post-operative Recovery Room

Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) upon arrival to the post-operative recovery room. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02960113)
Timeframe: 15 minutes after replacement of the uterus to arrival at post-anaesthesia care unit

Interventionunits on a scale (Mean)
Scopolamine Patch0.18
Acupressure Point P60.25
Scopolamine Patch + Acupressure Point P60.23

Number of Patients With Nausea

The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02960113)
Timeframe: Throughout the entire surgical procedure

InterventionParticipants (Count of Participants)
Scopolamine Patch40
Acupressure Point P639
Scopolamine Patch + Acupressure Point P646

Number of Patients With Vomiting

The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: Throughout the surgical procedure

InterventionParticipants (Count of Participants)
Scopolamine Patch24
Acupressure Point P625
Scopolamine Patch + Acupressure Point P631

Number of Patients With Vomiting After Eversion of the Uterus

Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After eversion of to replacement of the uterus

InterventionParticipants (Count of Participants)
Scopolamine Patch8
Acupressure Point P66
Scopolamine Patch + Acupressure Point P69

Number of Patients With Vomiting After Replacement of the Uterus

Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After replacement of the uterus and for next 15 minutes

InterventionParticipants (Count of Participants)
Scopolamine Patch10
Acupressure Point P615
Scopolamine Patch + Acupressure Point P612

Number of Patients With Vomiting After the Administration of the Regional Anesthesia Medications

Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: After the administration of the regional anesthesia medications until eversion of the uterus

InterventionParticipants (Count of Participants)
Scopolamine Patch20
Acupressure Point P615
Scopolamine Patch + Acupressure Point P620

Number of Patients With Vomiting Upon Arrival to the Post-operative Recovery Room

Objective assessments of whether or not the patients have vomited at this point in the surgical procedure will be done. The investigators will analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02960113)
Timeframe: From 15 minutes after replacement of the uterus until arrival at the post-anaesthesia care unit

InterventionParticipants (Count of Participants)
Scopolamine Patch1
Acupressure Point P61
Scopolamine Patch + Acupressure Point P64

Satisfaction With Intraoperative Antiemetic Treatment

Patients are asked their nausea and vomiting treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Patients are also asked their overall satisfaction with the procedure (0 = Not Satisfied, 10 = Extremely Satisfied). (NCT02960113)
Timeframe: Throughout the surgical procedure

Interventionunits on a scale (Mean)
Scopolamine Patch9.29
Acupressure Point P68.96
Scopolamine Patch + Acupressure Point P69.59

Reviews

10 reviews available for doxylamine and Emesis

ArticleYear
Misleading meta-analyses of observational studies may generate unjustified alarms: The case of medications for nausea and vomiting in pregnancy.
    Pharmacological research, 2021, Volume: 163

    Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans

2021
Doxylamine/pyridoxine for nausea and vomiting in pregnancy.
    Drug and therapeutics bulletin, 2019, Volume: 57, Issue:3

    Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Practice Guidelines

2019
The pharmacologic management of nausea and vomiting of pregnancy.
    The Journal of family practice, 2014, Volume: 63, Issue:2 Suppl

    Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Histamine H1 Antagonists; Humans; N

2014
The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin ®) for the treatment of nausea and vomiting of pregnancy.
    Paediatric drugs, 2014, Volume: 16, Issue:3

    Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans

2014
Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review.
    JAMA, 2016, 10-04, Volume: 316, Issue:13

    Topics: Acupuncture; Adrenal Cortex Hormones; Antiemetics; Doxylamine; Female; Histamine Antagonists; Humans

2016
Nausea and vomiting of pregnancy.
    American family physician, 2003, Jul-01, Volume: 68, Issue:1

    Topics: Acupressure; Antiemetics; Diagnosis, Differential; Doxylamine; Female; Humans; Hyperemesis Gravidaru

2003
Safety of drug therapy for nausea and vomiting of pregnancy.
    The Journal of family practice, 1980, Volume: 11, Issue:6

    Topics: Abnormalities, Drug-Induced; Antiemetics; Child; Dicyclomine; Doxylamine; Drug Combinations; Female;

1980
Alternative therapies of morning sickness.
    Clinical obstetrics and gynecology, 2001, Volume: 44, Issue:4

    Topics: Acupressure; Antiemetics; Complementary Therapies; Dicyclomine; Doxylamine; Drug Combinations; Femal

2001
Medical, social, and legal implications of treating nausea and vomiting of pregnancy.
    American journal of obstetrics and gynecology, 2002, Volume: 186, Issue:5 Suppl Un

    Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans

2002
Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
    Clinical pharmacy, 1986, Volume: 5, Issue:8

    Topics: Antiemetics; Antipsychotic Agents; Dicyclomine; Diphenhydramine; Doxylamine; Drug Combinations; Fema

1986

Trials

7 trials available for doxylamine and Emesis

ArticleYear
Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 
    Annals of internal medicine, 2023, Volume: 176, Issue:7

    Topics: Acupuncture Therapy; Antiemetics; Child; Doxylamine; Female; Humans; Nausea; Pregnancy; Pregnancy Co

2023
Ondansetron compared with doxylamine and pyridoxine for treatment of nausea in pregnancy: a randomized controlled trial.
    Obstetrics and gynecology, 2014, Volume: 124, Issue:4

    Topics: Adult; Antiemetics; Double-Blind Method; Doxylamine; Drug Therapy, Combination; Female; Follow-Up St

2014
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
    BMC pregnancy and childbirth, 2015, Mar-18, Volume: 15

    Topics: Adult; Antiemetics; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; Doxylamine; Drug

2015
8-Way Randomized Controlled Trial of Doxylamine, Pyridoxine and Dicyclomine for Nausea and Vomiting during Pregnancy: Restoration of Unpublished Information.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Cooperative Behavior; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Nausea; Physicians

2017
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
    American journal of obstetrics and gynecology, 2010, Volume: 203, Issue:6

    Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth

2010
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
    American journal of obstetrics and gynecology, 2010, Volume: 203, Issue:6

    Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth

2010
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
    American journal of obstetrics and gynecology, 2010, Volume: 203, Issue:6

    Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth

2010
Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial.
    American journal of obstetrics and gynecology, 2010, Volume: 203, Issue:6

    Topics: Adult; Delayed-Action Preparations; Dicyclomine; Dose-Response Relationship, Drug; Double-Blind Meth

2010
Determinants of adherence to delayed-release doxylamine and pyridoxine in patients with nausea and vomiting of pregnancy.
    Therapeutic drug monitoring, 2012, Volume: 34, Issue:5

    Topics: Adult; Antiemetics; Cohort Studies; Delayed-Action Preparations; Dicyclomine; Double-Blind Method; D

2012
Treatment of pregnancy sickness.
    British journal of obstetrics and gynaecology, 1977, Volume: 84, Issue:6

    Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dicyclomine; Double-Blind Method; Doxylamine;

1977

Other Studies

22 other studies available for doxylamine and Emesis

ArticleYear
Bioavailability of Cariban
    Drugs in R&D, 2023, Volume: 23, Issue:2

    Topics: Adult; Antiemetics; Biological Availability; Capsules; Delayed-Action Preparations; Doxylamine; Drug

2023
New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
    Journal of clinical epidemiology, 2019, Volume: 116

    Topics: Abnormalities, Drug-Induced; Adult; Antiemetics; Cohort Studies; Dicyclomine; Doxylamine; Drug Combi

2019
Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy.
    The Israel Medical Association journal : IMAJ, 2013, Volume: 15, Issue:1

    Topics: Administration, Oral; Adult; Antiemetics; Case-Control Studies; Dicyclomine; Dose-Response Relations

2013
Diclegis for nausea and vomiting of pregnancy.
    The Medical letter on drugs and therapeutics, 2013, Aug-05, Volume: 55, Issue:1422

    Topics: Antiemetics; Delayed-Action Preparations; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans

2013
Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin.
    The Journal of pediatrics, 2009, Volume: 155, Issue:1

    Topics: Adult; Antiemetics; Child; Child Development; Child, Preschool; Cohort Studies; Dicyclomine; Doxylam

2009
Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
    Therapeutic drug monitoring, 2011, Volume: 33, Issue:1

    Topics: Adult; Antiemetics; Biological Availability; Canada; Delayed-Action Preparations; Dicyclomine; Doxyl

2011
Bendectin and birth defects: hopefully, the final chapter.
    Birth defects research. Part A, Clinical and molecular teratology, 2003, Volume: 67, Issue:2

    Topics: Abnormalities, Drug-Induced; Adult; Adverse Drug Reaction Reporting Systems; Animals; Antiemetics; C

2003
Bendectin and birth defects. II: Ecological analyses.
    Birth defects research. Part A, Clinical and molecular teratology, 2003, Volume: 67, Issue:2

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Adverse Drug Reaction Reporting Systems

2003
Nausea and vomiting of pregnancy: treatment with bendectin.
    International record of medicine and general practice clinics, 1958, Volume: 171, Issue:9

    Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau

1958
Bendectin in the treatment of nausea and vomiting in pregnancy.
    Obstetrics and gynecology, 1959, Volume: 14

    Topics: Dicyclomine; Doxylamine; Drug Combinations; Histamine H1 Antagonists; Muscle Relaxants, Central; Nau

1959
Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003, Volume: 25, Issue:10

    Topics: Adult; Antiemetics; Dose-Response Relationship, Drug; Doxylamine; Drug Combinations; Female; Humans;

2003
American Gastroenterological Association institute medical position statement on the use of gastrointestinal medication in pregnancy.
    Gastroenterology, 2007, Volume: 132, Issue:2

    Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Gastrointestinal Agents; Gastrointe

2007
Debendox does not cause the Poland anomaly.
    Archives of disease in childhood, 1982, Volume: 57, Issue:6

    Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Antiemetics; Dicyclomine; Doxylamine; Drug Com

1982
Birth defects related to bendectin use in pregnancy. I. Oral clefts and cardiac defects.
    JAMA, 1981, Jun-12, Volume: 245, Issue:22

    Topics: Antiemetics; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Drug Combinations; Drug Evaluation; F

1981
Debendox and congenital malformations in Northern Ireland.
    British medical journal, 1980, Nov-22, Volume: 281, Issue:6252

    Topics: Abnormalities, Drug-Induced; Antiemetics; Cyclohexanecarboxylic Acids; Dicyclomine; Doxylamine; Drug

1980
Managing women with nausea and vomiting of pregnancy. Canadian consensus.
    Canadian family physician Medecin de famille canadien, 2000, Volume: 46

    Topics: Adult; Anti-Inflammatory Agents; Antiemetics; Asthma; Diagnosis, Differential; Doxylamine; Drug Ther

2000
Attitudes, management and consequences of nausea and vomiting of pregnancy in the United States and Canada.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2000, Volume: 70, Issue:3

    Topics: Adult; Antiemetics; Attitude; Attitude of Health Personnel; Canada; Cost of Illness; Dicyclomine; Di

2000
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.
    Journal of clinical pharmacology, 2001, Volume: 41, Issue:8

    Topics: Antiemetics; Doxylamine; Drug Combinations; Female; Humans; Infant, Newborn; Nausea; Pregnancy; Preg

2001
CDC study: no evidence for teratogenicity of Bendectin.
    JAMA, 1979, Dec-07, Volume: 242, Issue:23

    Topics: Abnormalities, Drug-Induced; Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Heart

1979
Bendectin and human congenital malformations.
    Teratology, 1989, Volume: 40, Issue:2

    Topics: Abnormalities, Drug-Induced; Central Nervous System; Dicyclomine; Digestive System Abnormalities; Do

1989
The management of nausea and vomiting during pregnancy.
    The Medical journal of Australia, 1987, Sep-21, Volume: 147, Issue:6

    Topics: Antiemetics; Dicyclomine; Doxylamine; Drug Combinations; Female; Humans; Legislation, Drug; Nausea;

1987
Debendox revisited.
    British journal of obstetrics and gynaecology, 1985, Volume: 92, Issue:8

    Topics: Abnormalities, Drug-Induced; Antiemetics; Cleft Lip; Cleft Palate; Dicyclomine; Doxylamine; Drug Com

1985